The company provides practice management, technology, clinical support, and business solutions to community-based oncology and other specialty practices, and sells financial, operational, and clinical solutions to pharmacies while providing consulting, outsourcing, technological, and other services. The prescription technology solutions segment combines automation and the ability to navigate the healthcare ecosystem to connect patients, pharmacies, providers, pharmacy benefit managers, health plans, and biopharma to address patients' medication access, affordability, and adherence challenges. This segment also offers prescription price transparency, benefit insight, dispensing support services, as well as third-party logistics and wholesale distribution support across various therapeutic categories and temperature ranges to biopharma customers throughout the product lifecycle. The medical-surgical solutions segment provides medical-surgical supply distribution, logistics, and other services to healthcare providers, including physician offices, surgery centers, nursing homes, hospital reference labs, and home health care agencies, offering national brand medical-surgical products as well as the company's own line of high-quality products through a network of distribution centers within the U.S. The international segment includes operations in Canada and Europe, delivering medicines, supplies, and information technology solutions throughout Canada. The company’s financial review highlights that gross profit increased primarily in the U.S. pharmaceutical segment driven by growth of specialty pharmaceuticals, last-in, first-out inventory credits, and increased contributions from technology services in the prescription technology solutions segment driven by higher volumes. The company evaluates the performance of its operating segments on various measures, including revenues and operating profit before interest expense and income taxes, and recognizes a discrete tax benefit related to the release of a valuation allowance based on management's reassessment of deferred tax assets. The company’s operational activities are influenced by market growth, including growing drug utilization, price increases, and newly launched products, which are partially offset by price deflation associated with branded to generic drug conversion. The company has recorded a provision for bad debts related to the bankruptcy of a customer, reflecting the impact of external influences on financial performance. The company’s strategic resource allocation includes investments in technology and operational efficiencies to drive long-term sustainable growth, with initiatives aimed at simplifying infrastructure and enhancing operational flexibility. The company’s ability to mobilize and deploy IT-based resources in combination with leveraging the value of other resources and capabilities is critical in transforming the firm into a competitive force. The company’s financial condition reflects significant investments in working capital, with cash flows from operations impacted by the timing of receipts from customers and inventory requirements. The company continues to evaluate its technology capabilities and investments to enhance business processes and support strategic management practices, ensuring alignment with organizational goals and market dynamics.